FirstWord

The biotech is gearing up for a Phase IIb trial of mizagliflozin in patients with post-bariatric hypoglycaemia.

Soficitinib (ICP-332) met the primary endpoint of the mid-stage portion of a Phase II/III study in patients with non-segmental vitiligo.

Lipfendra is authorised to reduce LDL-C in adults with hypercholesterolaemia, including heterozygous familial hypercholesterolaemia.

The company is advancing its Lead-212 PSMA-targeting alpha therapy into Phase III testing for metastatic prostate cancer.

Merck & Co.'s PD-1 inhibitor posted a win in endometrial cancer, while the European Commission approved Novo Nordisk's oral GLP-1 agonist for obesity.

With an FDA approval in hand for its oral PCSK9 inhibitor Lipfendra, Merck is gearing up to grow the overall PCSK9 market while setting the stage for potential fixed-dose combinations with other cardiovascular assets in its pipeline.

FirstWord is fielding a poll to US clinicians to gauge their awareness and willingness to use Merck & Co.'s Lipfendra (enlicitide).

SOLANA BEACH, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) (“Artelo” or the “Company”), a clinical-stage pharmaceutical company focused on modulating lipid-signall...

FirstWord will be speaking with a leading Alzheimer's expert about detailed Phase II CELIA data for Biogen and Ionis' diranersen, and what they say about it and other tau-targeting therapies.

EBD™ bispecific antibodies targeting both AβOs and hTfR showed improved brain penetration compared to the native anti-AβO antibodies, which may enable administration with a low-volume delivery device ...